Approximately 20%-40% of the adult population experiences recurrent outbreaks of herpes labialis, or cold sores [1] . In almost all cases, the disease is due to reactivation of chronic, latent herpes simplex virus type 1 infection from the ganglion of the trigeminal nerve. When the latent infection is activated by any one of a variety of triggers, virions descend through the sensory nerve axons and reinfect the peripheral epithelium. The new herpes labialis lesion matures within 8 h after onset [2] , leaving very little time for successful chemotherapeutic intervention.
The currently approved treatments for herpes labialis are acyclovir cream (Zovirax [GlaxoSmithKline]), penciclovir cream (Denavir [Novartis Consumer Health]), n-docosonal 10% cream (Abreva [GlaxoSmithKline]), and the oral prodrug of acyclovir, valacyclovir (Valtrex [GlaxoSmithKline]) [3] . A recent study of 1 or 2 high doses of famciclovir (Famvir [Novartis Farmaceutica]), the oral prodrug of penciclovir, also demonstrated efficacy in reducing the time to healing of herpes labialis lesions [4] . The topical treatments demonstrated limited efficacy and required multiple applications over several days [1] , whereas the oral prodrugs appeared to be more effective and required fewer doses. Multiple studies of acyclovir have suggested that the nominal efficacy of the topical formulation is the result of inadequate penetration of the drug into the target site of infection, the basal epidermis [5] [6] [7] [8] [9] .
Iontophoresis is defined as the use of a direct electric current to introduce ions of soluble salts into the tissues of the body, often for therapeutic purposes. Iontopho- resis has also been called iontherapy or electroosmosis. Iontophoresis has a long history of being used to enhance penetration of charged molecules through the skin [9] [10] [11] [12] [13] [14] . More specifically, recent in vitro studies have demonstrated increased transdermal transport of acyclovir with iontophoresis [15] [16] [17] , although those investigations used clinically impractical treatments of 30 min to 7 h of iontophoresis.
The current study describes work with a new wireless, portable, handheld, computer-controlled, iontophoretic device that allows rapid self-administration of acyclovir. The objective of this investigation was to test the iontophoretic device in a clinical study to determine whether improved transdermal delivery of acyclovir translates into better efficacy in treating herpes labialis.
MATERIALS AND METHODS

Active and Placebo Creams
The active cream used for this trial was an acyclovir 5% cream (acyclovir, Uquifa; cream formulation, MDS Pharma Services). The placebo cream (MDS Pharma Services) was identical to the acyclovir cream except for the replacement of acyclovir with titanium dioxide, which served to color the placebo cream the same shade of white as the active cream, thereby facilitating the blinding of this study.
Iontophoretic Device
The iontophoretic control unit (figure 1) is a cylindrical device, the size of a fountain pen, containing 2 standard AA batteries and a cuboid headpiece on which the medication reservoir is placed. A computer chip controls the intensity and duration of the electric current.
For this clinical study, a rectangular bandage-like applicator with a central drug reservoir and adhesive sides was tared on a balance, and a 250-mg dose of acyclovir 5% cream or placebo cream was spread evenly into the reservoir. The reservoir was then placed on the headpiece of the device over the positive treatment electrode (figure 2). The wings of the applicator, which contain a hydrogel adhesive intended to enhance conductivity, were pressed into place over the negative counter electrodes on the sides of the control unit. The subject was instructed to hold the device as a pencil with her fingers in contact with the hydrogel over the negative counter electrode. To complete the electrical circuit and begin treatment, the subject then was to place the device on the herpetic lesion. Treatment was administered for 10 min, in accordance with findings from a prior phase IIa study (data not shown). The device is programmed to shut off automatically after 10 min of treatment administration to prevent a prolonged exposure, and it cannot be reactivated for 24 h.
Study Design
This was a multicenter, randomized, double-blind, placebocontrolled clinic-initiated pilot study to evaluate the safety and efficacy of a single 10-min iontophoretic application of 5% acyclovir cream for the episodic treatment of erythema and papule/edema-stage herpes labialis in nonimmunocompromised patients. The trial was conducted in accordance with the 
Study Subjects
Healthy, noninstitutionalized subjects aged 18-75 years with a history of recurrent herpes labialis (у3 episodes/year) were recruited through advertisements. Subjects were excluded from the study if they had a cardiac pacemaker; a history of cardiac arrhythmias or conduction abnormalities; any evidence of active malignancy, immunodeficiency disease, use of immunosuppressive drugs, or use of systemic steroids; or a history of allergic or adverse response to acyclovir. Pregnant subjects were also excluded from the study.
Screening Visit
Written, informed consent was obtained from subjects, who were then screened for eligibility with a medical history. A pregnancy test was performed on all female subjects of childbearing potential. Subjects were instructed to call the clinic at the first signs or symptoms of an incipient herpes labialis lesion to arrange for a treatment visit.
Treatment Visit
To be certain that a lesion was in progress, the protocol required that subjects present early physical signs of herpes labialis (erythema or papule/edema) before treatment. Subjects who presented to the clinic with a new herpes labialis episode in the erythema or papule/edema stage were stratified by lesion stage and assigned in equal numbers to receive placebo or acyclovir cream. Subjects who presented with only prodromal symptoms or who had lesions that were too far advanced (vesicles or ulcers) to assess drug efficacy were not enrolled and were told to return at the time of their next episode. Subjects with lesions eligible for treatment were rescreened with respect to the inclusion/exclusion criteria, and female subjects of childbearing potential were again given pregnancy tests. The subjects received one 10-min iontophoretic application of either acyclovir 5% cream or placebo cream, according to the randomization schedule. The subject self-treated while being observed by the investigator or trained designee.
Follow-Up Visits
Lesion assessments. The investigator or trained designee scored each subject's lesion prior to dosing on day 1 and daily up to day 10. The lesion stage was scored according to the following scale: 1, erythema; 2, papule/edema; 3, vesicle/pustule; 4, ulcer; 5, soft or hard crust; and 6, healed (loss of crust, but may have erythema, residual swelling, or dry flaking).
Efficacy variables. The main outcome variable for efficacy was time to healing of classic lesions. Classic lesions are lesions that progress to the vesicle, ulcer, and/or crust lesion stages. Time to healing was defined as the time from the beginning of treatment until stage 6 (loss of crust). Lesions that did not progress beyond the papule stage-and, therefore, did not form a vesicle, ulcer, or crust-were termed "aborted" lesions. The healing time of aborted lesions was handled in 1 of 2 ways: (1) they were assigned a healing time of 0 h, or (2) they were excluded from the analysis on the basis that the durations of only the classic lesions were determined [18] . Subjects whose lesions did not reach stage 6 within the 10-day study period were considered censored in the statistical analysis.
Statistical Methods
The intent-to-treat (ITT) population consisted of all subjects randomized in the study who received active medication or placebo. The efficacy-evaluable population consisted of all subjects randomized into the study who received the intended treatment (active or placebo) and who had at least 3 posttreatment efficacy observations collected or who completed the study (lesion healed).
In general terms, categorical variables were summarized using counts and percentages, whereas continuous variables were summarized using mean, median, SD, number of observations, and minimum and maximum values. Analyses of demographic variables comparing the active treatment group with the placebo group were done using either the x 2 or Student's t test, depending on whether the variable was categorical or continuous. For time-to-healing and duration-of-pain data, KaplanMeier survival analysis methods were used to summarize the distributions for each group, and the Wilcoxon test was used to test for significant differences between the survival distributions for the active treatment and control group. All statistical analyses were performed at the .05 significance level, and all statistical tests were 2-sided.
RESULTS
Demographics.
The mean age for the 200 subjects was 42 years (range, 18-72 years). Seventy-four percent of the subjects were female, and 94% were white. There were no statistical differences between the 2 treatment groups in these demographic variables (table 1) .
Patient compliance and analysis population. The data analysis of the ITT population is presented. One patient in the active treatment group withdrew consent before any posttreatment assessments were done and, therefore, was not included in the ITT population. There was only 1 less subject in the efficacy-evaluable population, compared with the ITT population, and the results were essentially the same (data not shown).
Lesion assessment at treatment visit. The distribution of subjects in the treatment groups by lesion stage at start of treatment is shown in table 2. These distributions were not statistically significantly different. Aborted lesions. Table 3 compares the frequency of aborted lesions in each baseline lesion score stratum. In those subjects with an erythema baseline score, there was a tendency towards a significant difference in the frequency of aborted lesions, with 12 (46%) of 26 aborted lesions in the active group compared with 7 (24%) of 29 in the placebo group ( ). In contrast, P p .10 for subjects with a papule/edema baseline score, there was no difference between the active group and the placebo group in the frequency of aborted lesions, with 10% aborted lesions in each treatment group.
Time to healing. Table 4 presents the time to healing, with the aborted lesion healing time set to 0 h. The median time to healing was 35 h less in the active treatment group than the placebo group (113 h vs. 148 h;
). P p .02 The time-to-healing analysis was also performed separately for each baseline lesion score stratum. Table 4 presents results for time to healing for those subjects with an erythema baseline lesion score and for those subjects with a papule/edema baseline lesion score. For the erythema subgroup, the difference between the active treatment and placebo groups in time to healing was 71 h (49 h for active vs. 120 h for placebo; )-much P p .03 greater than what was seen for the overall population. In contrast, for those with a papule/edema baseline score, only a trend toward a difference was observed (122 h for active medication vs. 157 h for placebo;
). P p .11 Table 5 presents the time-to-healing analysis in which data from only those subjects whose lesions progressed to classic lesions were used. Therefore, all subjects who experienced aborted lesions were excluded from this analysis. With this approach, the median time to healing for the ITT population was 26.0 h less in the active treatment group than the placebo group (139 h vs. 165 h;
). As with the previous analysis, P p .03 a striking difference was observed when comparing subjects treated at the erythema stage with those treated at the papule/ edema stage. In those subjects treated at the erythema stage, a 72-h difference was noted between active and placebo (94 h vs. 166 h;
), compared with only a 25-h difference P p .15 between active and placebo (139 h vs. 164 h; ) for those P p .05 subjects treated at the papule/edema stage. A graph of the Kaplan-Meier survival function for time to healing (aborted lesions excluded), stratified by treatment group for the ITT population, is presented in figure 3A . The Kaplan-Meier survival function graphs for time to healing, stratified by treatment group for the baseline erythema lesion stage subpopulation, is presented in figure 3B .
Safety and tolerability analysis. There were a total of 17 adverse events among 12 patients in the active treatment group, compared with a total of 19 events among 13 patients in the placebo treatment group. In the active treatment group, 11 of the adverse events in 9 patients were judged to be treatment related, whereas in the placebo group, 6 of the adverse events in 4 patients were considered to be treatment related. Table 6 summarizes by treatment group those adverse events that were considered to have been related to treatment. The most common adverse event was an electrical sensation, with 2 reports in the acyclovir group and 1 report in the placebo group. In 1 of these instances of electrical sensation, the subject interrupted treatment, whereas the other 2 subjects completed treatment. All 3 adverse events were considered mild, and no treatment was required for any of them.
There were also single instances each of burned skin in 1 patient and erythema on the lip in another patient, both in the acyclovir group. The burned skin adverse event was considered to be mild; no treatment was required, and symptoms resolved in 2 days. The erythema adverse event was also mild and resolved the same day without treatment.
DISCUSSION
The design of this phase II clinical trial contains a unique component relative to prior studies of chemotherapy for herpes labialis: the delivery of a high dose of antiviral drug through a single topical treatment. The decisions to use only a single treatment and a treatment duration of 10 min were based on the known immunobiology associated with recurrent herpetic episodes [19] , previous clinical data from studies with valacyclovir [3] and with iontophoretically applied acyclovir cream [16] , and a prior phase IIa efficacy and safety study (data not shown). The median time to healing (aborted lesions given a value of 0 h) was 35 h less in the active treatment group than in the placebo group (113 h vs. 148 h; ), and for those P p .02 subjects with an erythema baseline lesion score, there was a marked increase to almost 72 h in the difference between the active treatment and placebo groups for the distribution of time to healing (49 h vs. 120 h;
), compared with the dif-P p .03 ference observed in the overall population. The drug efficacy in this study is particularly noteworthy, given that this was a clinic-initiated study in which subjects did not administer treatment until there was visible evidence of a lesion, whereas most recent trials have used patient-initiated treatment within 1 h after lesion onset. This study also demonstrated that self-administered, iontophoretically delivered acyclovir 5% cream is safe and well tolerated.
A brief, early window of therapeutic opportunity has been postulated for herpes labialis [2] , after which high local concentrations of endogenous IFN and other host immune responses abort further replication and render exogenous chemotherapy redundant [20] [21] [22] . As a result, achieving a high level of antiviral drug in the infected tissue early in the herpetic episode, during this therapeutic window of opportunity, is believed to be both critical and sufficient in realizing the efficacy of antiviral chemotherapy. This premise has been supported by recent studies of 1-dose famciclovir [4] and 1-day, high-dose valacyclovir treatment [3] . Our results with a single iontophoretic antiviral treatment provide further evidence for this dosing strategy.
Recently published results demonstrate that acyclovir 5% cream applied 5 times daily for 4 days (20 administrations), initiated within 1 h of the onset of signs or symptoms of a recurrent herpes labialis episode, resulted in a 0.5-0.6-day decrease in healing time [23] . Penciclovir 1% cream (Denavir) produced similar results when administered under the same conditions [24, 25] . Oral treatment with valacyclovir (1-day decrease) or famciclovir (2-day decrease) appeared to produce better results [3, 4] . In the current study of clinic-initiated treatment of established lesions, the healing time in drugtreated subjects was decreased by 1.5 days, and among a subset of subjects treated in the erythema stage, there was a 3-day decrease in healing time. These comparative judgments must be tempered by the small sample size of the present trial, as well as the understanding that comparisons of relative merit between different treatments can only be made with certainty in head-to-head trials.
The time-to-healing analysis in this study focused on classic lesions. This type of analysis is important, because the lesion stages from vesicle to the loss of crust are the most uncomfortable and disfiguring parts of the episode. In prior studies, this has been done by excluding aborted lesions and analyzing the classic lesion subset. We looked at the data in this way, but we also used a different procedure-assigning aborted lesions a healing time of 0 h-as described recently by S.L.S. and Hill [18] . The advantage of this approach is that all study patients are included in the analysis. If the test therapy affects lesion development sufficient to increase the frequency of aborted lesions, then this beneficial effect will be captured by the healing time (aborted lesion healing time set to 0 h) such as to present a global, more definitive account of the drug's activity in the trial.
Of 200 subjects treated, there were a total of 17 treatmentrelated adverse events in 13 patients. Of those, 2 were considered to be moderate in severity, whereas the others were all judged to be mild. The most common adverse event was a mild electrical sensation, reported in 3 patients. All 3 of these adverse events occurred at a single clinical site, in 3 of the 4 patients treated at the site; therefore, they may represent a site-specific procedural issue. There was also a single instance (at a different clinical site) of a mild burn at the treatment site that required no treatment and resolved within 2 days. With exception of these few events, the iontophoretic procedure was well tolerated by the study subjects.
New studies are planned to confirm the efficacy of iontophoretically administered acyclovir. These trials, using a modified version of the iontophoretic device, will be subject initiated, so that treatment can be given immediately after the first signs or symptoms of a recurrence. 
